Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
OwnerDonald J. Zack, Derek S. Welsbieinventors
Life of this patent
Estimating the term…
Abstract
Drug targets, pathways, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.
Claims12
-22. (canceled)
A method for inhibiting retinal ganglion cell injury or death, which comprises contacting a retinal ganglion cell with at least one small molecule mixed-lineage kinase (MLK) inhibitor that inhibits the expression or activity of two or more protein kinases, wherein the two or more protein kinases are selected from MAP3K12, MAP3K13, MAP3K14, MAP2K7, MAP2K4, LYN, PLK3, PFKP MARK3, MARK2, TAOK1, IKBKB, BRSK2, PBK, PRKCH, TESK1, Csnk1e, Oxsr1, Tgfbr2, Mapk10, PFTK1, ERN2, AK2, HSPB8, FRAP1, DGUOK, ERN1, STK32B, PIK3C2G, BCR, DYRK1A, DYRK1B, PNCK, EIF2AK1, PKD2L1, NRK, Endothelin Receptor Type B, and TLK2.
Dependencies are inferred from the claim text.